期刊
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
卷 147, 期 6, 页码 332-336出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1334-2135
关键词
nephrotic syndrome; minimal change disease; MCD focal and segmental glomerulosklerosis; FSGS; FOrMe; KDIGO 2021
The new 2021 KDIGO Guidelines provide detailed classification and treatment recommendations for nephrotic syndrome caused by minimal change disease (MCD) and focal and segmental glomerulosclerosis (FSGS), including the distinction between primary, secondary, and genetic causes, as well as the selection and alternatives for treatment drugs. In addition, it is recommended to include patients in clinical registries to ensure proper treatment and genetic testing, and to utilize national registries for refining individualized medicine.
Advances in basic and clinical research have improved our understanding of the pathomechanisms underlying nephrotic syndrome caused by minimal change disease (MCD) and focal and segmental glomerulosclerosis (FSGS). These advances are reflected in the new 2021 KDIGO-Guidelines, which emphasize the clear distinction between primary, secondary and genetic causes. Proper classification is critical, as it directly affects the therapy of choice. While glucocorticoids still play a central in inducing remission in primary forms, calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide and rituximab (off label) are viable adjuncts/alternatives to reduce or replace glucocorticoids in case of side effects or contraindications. Since SGLT-2-inhibitors have shown renoprotective effects in non-diabetic patients and may help to reduce proteinuria, they should be considered in all (adult) patients with chronic kidney disease, including MCD and FSGS patients. In the near future, Sparsentan, an endothelin type A and angiotensin receptor blocker may be added to the growing arsenal of proteinuria-reducing agents, with a phase 3 trail expected to be completed in late 2022. Finally, we recommend the inclusion of all MCD/FSGS patients in clinical registries (e. g. FOrMe Registry in Germany) to ensure adequate therapy and genetic testing if indicated. In addition, national registries are an invaluable source of clinical data that helps to refine our therapies towards individualized medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据